Cardio Societies: Antihypertenisves & COVID-19
Posted: March 20, 2020
If you are on an Angiotensin Converting Enzyme Inhibitor (ACE Inhibitor: they all end in “-pril”, as in lisinopril) or an Angiotensin Receptor Blocker (ARB – they all end in “-sartan”, as in olmesartan), for hypertension or high blood pressure, heart failure or cardiomyopathy/congestive heart failure, or for renal (kidney) protection in patients with diabetes or kidney disease, please stay on them during this COVID-19 crisis!
In case there are questions from Low T Center patients with hypertension on ACE Inhibitors or ARB’s:
- ARBs “might” actually represent a “tentative” SARS-CoV-2 therapeutic
- Three American professional cardiology societies have issued a joint statement urging continuation of renin-angiotensin-aldosterone system (RAAS) antagonists in patients, despite theoretical concerns that their use might worsen outcomes in the event of infection with COVID-19.
The new statement was issued jointly by the American Heart Association (AHA), American College of Cardiology (ACC), and Heart Failure Society of America (HFSA) on March 17 in response to the current COVID-19 crisis.
It follows similar recent statements from the European Society of Cardiology (ESC), as reported yesterday by Medscape Medical News, and the European Society of Hypertension, Canadian Cardiovascular Society, and International Society of Hypertension, among others.
Disclaimer: This article is made available for general, entertainment and educational purposes only. The opinions expressed herein do not necessarily reflect those of Low T Center. You should always seek the advice of a licensed healthcare professional.